320 related articles for article (PubMed ID: 18427143)
1. Cardiac allograft vasculopathy: recent developments.
Schmauss D; Weis M
Circulation; 2008 Apr; 117(16):2131-41. PubMed ID: 18427143
[TBL] [Abstract][Full Text] [Related]
2. Treatment and prophylaxis of cardiac allograft vasculopathy.
Wang SS
Transplant Proc; 2008 Oct; 40(8):2609-10. PubMed ID: 18929815
[TBL] [Abstract][Full Text] [Related]
3. The continuing challenge of cardiac transplant arteriosclerosis.
Weis M; Meiser BM; Reichart B; von Scheidt W
Cardiologia; 1998 Aug; 43(8):777-87. PubMed ID: 9808867
[TBL] [Abstract][Full Text] [Related]
4. Cardiac allograft vasculopathy.
Lee MS; Finch W; Weisz G; Kirtane AJ
Rev Cardiovasc Med; 2011; 12(3):143-52. PubMed ID: 22080925
[TBL] [Abstract][Full Text] [Related]
5. Follow-up study on the utility of von Willebrand factor levels in the diagnosis of cardiac allograft vasculopathy.
Martínez-Dolz L; Almenar L; Reganon E; Vila V; Chamorro C; Andrés L; Martínez-Sales V; Moro J; Agüero J; Sánchez-Lázaro I; Salvador A
J Heart Lung Transplant; 2008 Jul; 27(7):760-6. PubMed ID: 18582806
[TBL] [Abstract][Full Text] [Related]
6. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma".
Valantine HA
Transplantation; 2003 Sep; 76(6):891-9. PubMed ID: 14508350
[TBL] [Abstract][Full Text] [Related]
7. Cardiac allograft vasculopathy: a review.
Ramzy D; Rao V; Brahm J; Miriuka S; Delgado D; Ross HJ
Can J Surg; 2005 Aug; 48(4):319-27. PubMed ID: 16149368
[TBL] [Abstract][Full Text] [Related]
8. Proliferation signal inhibitors and cardiac allograft vasculopathy.
Raichlin E; Kushwaha SS
Curr Opin Organ Transplant; 2008 Oct; 13(5):543-50. PubMed ID: 19060540
[TBL] [Abstract][Full Text] [Related]
9. Influence of traditional cardiovascular risk factors in the recipient on the development of cardiac allograft vasculopathy after heart transplantation.
Sánchez Lázaro IJ; Almenar Bonet L; Moro López J; Sánchez Lacuesta E; Martínez-Dolz L; Agüero Ramón-Llín J; Andrés Lalaguna L; Cano Pérez O; Ortiz Martínez V; Buendía Fuentes F; Salvador Sanz A
Transplant Proc; 2008 Nov; 40(9):3056-7. PubMed ID: 19010192
[TBL] [Abstract][Full Text] [Related]
10. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation.
Delgado JF; Manito N; Segovia J; Almenar L; Arizón JM; Campreciós M; Crespo-Leiro MG; Díaz B; González-Vílchez F; Mirabet S; Palomo J; Roig E; de la Torre JM
Transplant Rev (Orlando); 2009 Apr; 23(2):69-79. PubMed ID: 19298938
[TBL] [Abstract][Full Text] [Related]
11. Allograft vasculopathy versus atherosclerosis.
Rahmani M; Cruz RP; Granville DJ; McManus BM
Circ Res; 2006 Oct; 99(8):801-15. PubMed ID: 17038650
[TBL] [Abstract][Full Text] [Related]
12. The influence of cytomegalovirus infection, confirmed by pp65 antigen presence, on the development of cardiac allograft vasculopathy.
Zakliczyński M; Krynicka-Mazurek A; Pyka Ł; Trybunia D; Nadziakiewicz P; Przybylski R; Zembala M
Transplant Proc; 2007 Nov; 39(9):2866-9. PubMed ID: 18022004
[TBL] [Abstract][Full Text] [Related]
13. Assessment of immunological markers as mediators of graft vasculopathy development in heart transplantation.
Mirabet S; Gelpí C; Roldán C; Brossa V; Mendoza CA; Lopez L; Molto E; Alvaro Y; Martinez V; Padró JM; Roig E
Transplant Proc; 2011; 43(6):2253-6. PubMed ID: 21839249
[TBL] [Abstract][Full Text] [Related]
14. Cardiac allograft vasculopathy: current knowledge and future direction.
Colvin-Adams M; Agnihotri A
Clin Transplant; 2011; 25(2):175-84. PubMed ID: 21457328
[TBL] [Abstract][Full Text] [Related]
15. Cardiac allograft vasculopathy: current concepts and treatment.
Waller J; Brook NR; Nicholson ML
Transpl Int; 2003 Jun; 16(6):367-75. PubMed ID: 12756523
[TBL] [Abstract][Full Text] [Related]
16. Delayed onset of cardiac allograft vasculopathy by induction therapy using anti-thymocyte globulin.
Zhang R; Haverich A; Strüber M; Simon A; Bara C
J Heart Lung Transplant; 2008 Jun; 27(6):603-9. PubMed ID: 18503958
[TBL] [Abstract][Full Text] [Related]
17. Cardiac allograft vasculopathy: do adipocytes bridge alloimmune and metabolic risk factors?
Wehner JR; Baldwin WM
Curr Opin Organ Transplant; 2010 Oct; 15(5):639-44. PubMed ID: 20689436
[TBL] [Abstract][Full Text] [Related]
18. Cardiac allograft vasculopathy after cardiac transplantation and hormone therapy: positive effects?
Lange V; Renner A; Sagstetter M; Harms H; Elert O
Transplantation; 2006 Jul; 82(2):234-40. PubMed ID: 16858287
[TBL] [Abstract][Full Text] [Related]
19. Immunological and Fibrotic Mechanisms in Cardiac Allograft Vasculopathy.
Jansen MA; Otten HG; de Weger RA; Huibers MM
Transplantation; 2015 Dec; 99(12):2467-75. PubMed ID: 26285017
[TBL] [Abstract][Full Text] [Related]
20. Current therapies for cardiac allograft vasculopathy in children.
Kindel SJ; Pahl E
Congenit Heart Dis; 2012; 7(4):324-35. PubMed ID: 22613206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
